title: A killer choice for cancer immunotherapy.
abstract: The promise of cell-based immunotherapies for the treatment of cancer offers the potential of therapeutic synergy with chemo- and radiotherapies that may overcome current limitations leading to durable responses and prevention of recurrence. There is a wide array of cell-based immunotherapies that are either poised to enter cancer clinical trials or are in clinical trials, and many are showing some success. Yet within this field, there are clear obstacles that need to be overcome, including limited access across tissue barriers, development of antigen tolerance, and the immunosuppressive microenvironment of tumors. Through an understanding of immune cell signaling and trafficking, immune cell populations can be selected for adoptive transfer, and delivery strategies can be developed that circumvent these obstacles to effectively direct populations of cells with robust anti-tumor efficacy to the target. Within the realm of immune cell therapies, cytokine-induced killer (CIK) cells have demonstrated promising trafficking patterns, effective delivery of synergistic therapeutics, and stand-alone efficacy. Here, we discuss the next generation of CIK therapies and their application for the effective treatment of a wide variety of cancers.
authors.affiliation: Molecular Imaging Program at Stanford (MIPS), Department of Pediatrics, Stanford Center for Photomedicine, Stanford University School of Medicine, Clark Center, East Wing E150, 318 Campus Drive, Stanford, CA, 94305-5439, USA.
authors.forename: Tobi L
authors.initials: TL
authors.lastname: Schmidt
authors.forename: Robert S
authors.initials: RS
authors.lastname: Negrin
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Contag
mesh_terms: D000818:Animals; D055612:Cytokine-Induced Killer Cells / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*